Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium In Orally Disintegrating Tablets: Formulation Strategies And Performance Optimization

NOV 17, 202662 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose Sodium serves as a critical superdisintegrant in Orally Disintegrating Tablets (ODTs), enabling rapid disintegration within seconds upon contact with saliva. This cellulose-derived excipient demonstrates superior performance at concentrations of 2–8% w/w, significantly outperforming alternative disintegrants such as crospovidone and sodium starch glycolate in achieving target disintegration times below 30 seconds while maintaining adequate tablet hardness 1. Its unique swelling mechanism and distribution strategy between intra-granular and extra-granular phases make it indispensable for formulating patient-compliant ODT dosage forms across therapeutic categories.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Disintegration Mechanism Of Croscarmellose Sodium In ODT Systems

Croscarmellose Sodium (also known as Ac-Di-Sol®) is an internally cross-linked sodium carboxymethylcellulose characterized by its rapid swelling capacity and water-wicking properties 3. Unlike linear cellulose derivatives, the cross-linked three-dimensional network structure allows the polymer chains to absorb water rapidly (up to 8–10 times its own weight within seconds) without dissolving, thereby generating substantial localized swelling pressure that disrupts tablet matrix integrity 7. This mechanism is fundamentally different from crospovidone, which relies primarily on capillary action, and sodium starch glycolate, which exhibits slower hydration kinetics 15.

The superdisintegrant classification of Croscarmellose Sodium stems from its ability to achieve effective disintegration at significantly lower concentrations (2–4% w/w) compared to conventional disintegrants like corn starch (10–15% w/w) 6. Comparative studies demonstrate that at 2% concentration, Croscarmellose Sodium achieves disintegration times of approximately 18–22 seconds in ODTs compressed at 6–8 kN, whereas crospovidone (PVP XL-10) at 5% concentration requires 30–40 seconds under identical conditions 7. The molecular-level explanation involves the ionization of carboxymethyl groups (–CH₂COO⁻Na⁺) in aqueous media, creating electrostatic repulsion between polymer chains that amplifies the swelling force and accelerates matrix breakdown 37.

Key structural parameters influencing disintegration performance include:

  • Degree of cross-linking: Optimal cross-link density (typically 0.15–0.25 mol/mol) balances swelling capacity with structural integrity; excessive cross-linking reduces water uptake while insufficient cross-linking causes premature dissolution 3
  • Particle size distribution: Croscarmellose Sodium with mean particle diameter of 30–50 μm provides maximum surface area for rapid hydration, though particles up to 200 μm remain effective in ODT formulations 8
  • Substitution degree: Carboxymethyl substitution of 0.6–0.9 per glucose unit ensures adequate hydrophilicity without compromising the polymer's insolubility 3

The disintegration kinetics follow a two-stage process: initial rapid water penetration (0–5 seconds) driven by capillary forces through inter-particulate voids, followed by explosive swelling (5–20 seconds) as Croscarmellose Sodium particles expand and generate disruptive forces exceeding the tablet's tensile strength (typically 0.5–2.0 MPa for ODTs) 7. Texture analyzer studies reveal that Croscarmellose Sodium-containing ODTs exhibit a gradual softening pattern with earlier initiation of disintegration compared to the delayed-then-sudden pattern observed with crospovidone, resulting in superior mouthfeel perception by 80% of trained panelists 7.

Optimal Concentration Ranges And Formulation Guidelines For Croscarmellose Sodium

Extensive formulation development studies establish that Croscarmellose Sodium functions optimally in Orally Disintegrating Tablets at concentrations between 3.5% and 8.0% w/w of total tablet weight 126. This range represents a critical balance between achieving rapid disintegration (target: <30 seconds) and maintaining sufficient mechanical strength (hardness: 40–70 N; tensile strength: >0.5 MPa) to withstand manufacturing, packaging, and handling stresses 7.

Concentration-Performance Relationships:

  • 2.0% w/w: Minimum effective concentration for ODTs with polyol-based matrices (mannitol, sorbitol); achieves 18-second disintegration at 6 kN compression force but may exhibit batch-to-batch variability 7
  • 3.5–4.0% w/w: Lower threshold for robust formulations; provides disintegration times of 25–30 seconds with hardness values of 45–55 N 16
  • 5.0–7.0% w/w: Optimal range for most therapeutic applications; 7% concentration yields approximately 20-second disintegration in orodispersible domperidone tablets while maintaining hardness of 52–54 N 126
  • 8.0% w/w: Upper practical limit; higher concentrations do not significantly improve disintegration but may compromise tablet hardness and increase friability 1

Comparative analysis against alternative superdisintegrants demonstrates Croscarmellose Sodium's efficiency advantage: achieving equivalent disintegration performance at 2% versus 5% for crospovidone (PVP XL-10) or sodium starch glycolate 7. Corn starch, crospovidone, and croscarmellose calcium were systematically evaluated and rejected due to inadequate disintegration times and/or mechanical defects (cleavage, high friability) 126.

Phase Distribution Strategy:

A critical formulation parameter unique to Croscarmellose Sodium in ODTs involves its distribution between the intra-granular (internal) and extra-granular (external) phases during tablet manufacturing 126. Optimal disintegration kinetics are achieved by allocating approximately 50% of total Croscarmellose Sodium to each phase—a 50:50 distribution yields 20-second disintegration, whereas 25:75 or 75:25 distributions result in disintegration times exceeding 40 seconds (more than double) 16. This phenomenon is attributed to the dual-action mechanism: intra-granular Croscarmellose Sodium disrupts granule integrity from within, while extra-granular material facilitates inter-granular separation and water penetration pathways 2.

Granulation Process Considerations:

When incorporating Croscarmellose Sodium via wet granulation, the material should be prepared as an aqueous slurry at 2–15% concentration relative to the active pharmaceutical ingredient (API) weight, preferably 5–12% 5. Critical process controls include:

  • Limiting water quantity to only that required for granulation to prevent premature Croscarmellose Sodium dissolution 5
  • Minimizing time between slurry preparation and granulation initiation (<15 minutes) to preserve the disintegrant's coating effectiveness on API particles 5
  • Maintaining granulation temperature at 30–100°C during subsequent drying to avoid thermal degradation 8

The slurry-based incorporation method enhances API particle coating, which is particularly beneficial for water-soluble actives that might otherwise exhibit delayed release 5. Notably, sodium starch glycolate develops undesirable ropy consistency in slurry form, while crospovidone fails to provide adequate particle coverage—both factors contributing to Croscarmellose Sodium's preferential selection 5.

Synergistic Excipient Combinations In Croscarmellose Sodium ODT Formulations

The performance of Croscarmellose Sodium in Orally Disintegrating Tablets is profoundly influenced by co-formulated excipients, particularly fillers/diluents, binders, and lubricants. Rational excipient selection based on physicochemical compatibility and functional synergy is essential for achieving target product profiles.

Filler/Diluent Selection And Particle Size Optimization

Mannitol emerges as the preferred diluent for Croscarmellose Sodium-based ODTs, typically incorporated at 55–70% w/w with particle size range of 30–300 μm (mean diameter ~160 μm) 126. Comparative evaluations demonstrate that lactose, sorbitol, and excessive microcrystalline cellulose (MCC) all produce unacceptably long disintegration times or undesirable organoleptic properties 126. Mannitol's advantages include:

  • Rapid dissolution kinetics that complement Croscarmellose Sodium's swelling action 2
  • Pleasant cooling sensation and sweet taste (sweetness ~50–70% of sucrose) that mask API bitterness 6
  • Non-hygroscopic nature (equilibrium moisture uptake <0.3% at 80% RH) ensuring tablet stability 2
  • Excellent compressibility enabling direct compression at moderate forces (6–10 kN) 1

Spray-dried mannitol specifically demonstrates superior performance in low-superdisintegrant ODT formulations (0.5–2.0% Croscarmellose Sodium), achieving <30-second disintegration after four months of accelerated stability testing (40°C/75% RH) 7.

Microcrystalline Cellulose (MCC) serves dual functions as binder and secondary filler at 10–20% w/w concentration 126. Particle size significantly impacts ODT performance:

  • MCC with 100 μm mean diameter (e.g., Ceolus PH-102) yields optimal balance: hardness 52 N, disintegration time 5 seconds, intraoral disintegration 6 seconds 9
  • Finer grades (50 μm, PH-101) reduce hardness to 47 N while extending intraoral disintegration to 20 seconds 9
  • Ultrafine grades (17 μm, F20) further compromise intraoral disintegration (25 seconds) despite adequate in vitro performance 9

Excessive MCC content (>25% w/w) creates production challenges with conventional tablet presses due to increased ejection forces and causes undesirable gustatory perception (cellulose mouthfeel) 26. The recommended MCC range of 10–20% provides sufficient binding without interfering with Croscarmellose Sodium's disintegration mechanism 36.

Co-Processed Excipient Systems

Advanced ODT formulations employ co-processed excipients combining MCC with other functional components. A particularly effective system comprises 75–95% MCC with 5–25% calcium-sodium alginate complex at 10–50% total tablet weight, used alongside 1–6% Croscarmellose Sodium and 10–50% additional MCC 3. This co-processed additive enhances:

  • Tablet compressibility for difficult-to-compress APIs 3
  • Suspension formation upon disintegration (beneficial for pediatric/geriatric populations) 3
  • Dose uniformity through improved powder flow (angle of repose <35°) 3

Recent innovations include self-disintegrating co-processed excipients manufactured by spray-drying or flash-drying homogeneous slurries of cellulose binder, MCC, and 0.5–15% Croscarmellose Sodium at 30–100°C 8. These systems exhibit mean particle size of 90–150 μm and bulk density of 0.25–0.50 g/mL, optimized for direct compression ODT manufacturing 8.

Lubricant Selection And Concentration Control

Magnesium stearate at 0.5–1.5% w/w represents the standard lubricant choice for Croscarmellose Sodium ODT formulations 126. Critical considerations include:

  • Concentrations ≤0.8% w/w are preferred to minimize hydrophobic interference with water penetration and Croscarmellose Sodium hydration 7
  • External lubrication methods (applying lubricant to die walls rather than blending with powder) can reduce required concentration to 0.2–0.5% while maintaining adequate lubrication 7
  • Over-lubrication (>1.5%) significantly extends disintegration time by creating hydrophobic barriers around Croscarmellose Sodium particles 6

Alternative lubricants such as sodium stearyl fumarate, stearic acid, and talc may be employed at 0.2–1.0% w/w, with sodium stearyl fumarate offering reduced hydrophobicity compared to magnesium stearate 8.

Binder And Polymer Additives

While Croscarmellose Sodium itself provides some binding capacity through its fibrous structure, additional binders may be incorporated for specific applications. Maltodextrin at ≥2% w/w serves as a water-soluble binder in orodispersible domperidone formulations, contributing to granule integrity without compromising disintegration 126.

Emerging formulations incorporate 0.5–5% w/w of hydrophobic polymers—including (meth)acrylic polymers, ethyl cellulose, cellulose acetate, hydroxypropylmethylcellulose acetate succinate (HPMCAS), or hydroxypropylmethylcellulose phthalate (HPMCP)—to enhance tablet moldability and moisture resistance while maintaining disintegration performance when combined with 3–8% Croscarmellose Sodium 4. These polymers create a controlled-release microenvironment that modulates water ingress without preventing Croscarmellose Sodium activation.

Manufacturing Process Parameters And Quality Control For Croscarmellose Sodium ODTs

The translation of Croscarmellose Sodium formulations from laboratory-scale development to commercial manufacturing requires precise control of multiple process parameters to ensure consistent disintegration performance, mechanical strength, and stability.

Compression Force And Tablet Hardness Relationships

Compression force directly influences the balance between tablet hardness and disintegration time. Systematic studies demonstrate:

  • 6 kN compression: ODTs with 2% Croscarmellose Sodium achieve 18-second disintegration but may exhibit marginal hardness (40–45 N) and increased friability (>1.0%) 7
  • 8 kN compression: Same formulation yields 22-second disintegration with improved hardness (50–55 N) and acceptable friability (<0.8%) 7
  • 10–12 kN compression: Hardness increases to 60–70 N but disintegration time extends to 30–40 seconds, approaching the upper acceptable limit 7

The optimal compression force window for Croscarmellose Sodium ODTs typically ranges from 7–9 kN, producing tablets with tensile strength of 0.5–1.5 MPa—sufficient to withstand a 1-meter drop test while maintaining <25-second disintegration 7. Excessive compression (>12 kN) causes plastic deformation of Croscarmellose Sodium particles, reducing their swelling capacity and significantly impairing disintegration kinetics 7.

Granulation Methods And Moisture Control

Wet Granulation Approach:

When employing wet granulation with Croscarmellose Sodium slurry as the granulating fluid 5:

  1. Prepare aqueous slurry of Croscarmellose Sodium at 5–12% w/w relative to API weight
  2. Limit slurry preparation-to-use time to <15 minutes to prevent disintegrant dissolution
  3. Granulate API with slurry in high-shear mixer at 200–400 rpm impeller speed for 3–8 minutes
  4. Dry granules in fluid bed dryer at 50–60°C inlet temperature until moisture content reaches 2–4% w/w
  5. Mill dried granules through 1270 μm (12 mesh) screen
  6. Blend milled granules with extra-granular Croscarmellose Sodium, MCC, and lubricant for 5–10 minutes at 20–30 rpm

This process ensures uniform Croscarmellose Sodium distribution and optimal particle coating of the API 5. Critical moisture control is essential—residual moisture >5% w/w can cause premature Croscarmellose Sodium activation during storage, while <1% w/w may result in brittle granules with poor compressibility 8.

Direct Compression Approach:

For direct compression ODT formulations (increasingly preferred for manufacturing efficiency) 7:

  1. Pre-blend API with 50% of total Croscarmellose Sodium and mannitol for 10–15 minutes
  2. Add MCC and remaining Croscar
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
PIERRE FABRE MEDICAMENTLow-dose therapeutic orally disintegrating tablets requiring rapid disintegration (<30 seconds) for patient populations with swallowing difficulties, particularly for antiemetic and gastrointestinal medications.Orodispersible Domperidone TabletsAchieved 20-second oral disintegration time using 7% croscarmellose sodium with 50:50 intra-granular/extra-granular distribution, maintaining tablet hardness of 52-54N while outperforming corn starch, crospovidone and croscarmellose calcium alternatives.
FMC CORPORATIONOrally disintegrating tablets for resource-limited saliva environments requiring rapid medication delivery, pharmaceutical suspension tablets for pediatric and geriatric populations needing measured-dose suspensions.Ac-Di-Sol (Croscarmellose Sodium)Demonstrated superior disintegration efficiency at 2% concentration achieving 18-22 second disintegration times compared to 5% crospovidone requiring 30-40 seconds, with preferred gradual softening pattern and smoother mouthfeel rated by 80% of panelists.
DAICEL CORPORATIONOrally disintegrating tablets requiring improved mechanical strength and moisture stability during manufacturing, packaging and handling in humid environments while preserving fast disintegration properties.ODT Additive CompositionEnhanced tablet moldability by combining 3-8% croscarmellose sodium with 0.5-5% hydrophobic polymers (acrylic/cellulosic derivatives) while maintaining rapid disintegration and moisture resistance in orally disintegrating formulations.
Reference
  • Orodispersible domperidone tablets
    PatentInactiveCA2645629A1
    View detail
  • Orodispersible domperidone tablets
    PatentInactiveIN8373DELNP2008A
    View detail
  • Pharmaceutical suspension tablet compositions
    PatentWO1999030689A1
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png